Clostridium difficile is labeled as one of the organisms of greatest concern for antibiotic resistance by the National Institutes of Health. 

Most healthcare practitioners associate it with acute colitis and diarrhea. However, it can also colonize the gastrointestinal tract, creating chronic symptoms that are harder to recognize.

Colonization of a number of problematic Clostridia species (and the metabolites they produce) can create neurological irritation and neurotransmitter imbalances, and has been implicated in:

  • Attention issues
  • Mood disorders
  • Neurological conditions

In this three-part series, Dr. Kurt Woeller delivers clinically relevant information that comes from years of working with neurologically symptomatic patients, his experience in specialized testing, and from a place of commitment to excellent patient care.

Dive into Part 1 where Dr. Woeller introduces the breadth of alternative symptoms that can manifest with Clostridium difficile (C. diff) and other pathogenic species.Stay tuned for upcoming Parts 2 and 3 where Dr. Woeller identifies methods most effective for detecting C. diff and discusses his most trusted therapeutics for addressing positive test results.Best for your health,
image

Kurt N. Woeller, DO, has been a functional and integrative medicine physician and a biomedical autism treatment specialist for over two decades. A respected author, international lecturer, and educator, he provides healthcare practitioner education through his online Integrative Medicine Academy.

Dr. Woeller serves as a clinical consultant and educator for both BioHealth Laboratory and Great Plains Laboratory (GPL). At GPL, he teaches the Organic Acid Test (OAT) interpretation and implementation course.

At his private practice in Bend, OR, he focuses on specialized diagnostic testing and treatment for individuals with complex medical conditions like autism, autoimmune and neurological disorders.

_____________________

For more:

 
  •  

https://www.globenewswire.com/en/news-release/2021/05/04/2222816/0/en/Tarsus-Pharmaceuticals-Inc-Announces-FDA-Acceptance-of-Investigational-New-Drug-Application-for-TP-05-for-Lyme-Disease-Prevention

Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention

Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention

Allows initiation of Phase 1 study to evaluate safety, pharmacokinetics, and dosing

More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms

IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease. With this IND acceptance, Tarsus will initiate a Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of TP-05 in healthy volunteers. Study initiation is anticipated in July.

“We are pleased that the FDA has accepted the IND for TP-05, which is an important milestone in our pipeline development. Currently, there are no approved pharmacological prophylactic options for tick kill and preventing transmission of Lyme disease, which has the potential to cause severe, often debilitating symptoms with permanent and irreversible damage,” said Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus. “There is a significant unmet need for a therapeutic to quickly and reliably prevent this disease that can lead to poor outcomes for so many people. We look forward to initiating our clinical development program for TP-05 and advancing the path for this much-needed therapeutic for Lyme disease prevention.”

Lyme disease is transmitted to humans after the bite of a blacklegged tick infected with the Borrelia bacteria. It is the most common vector-borne disease in the United States and can result in inflammation, nerve, joint and muscle pain and swelling, numbness, shortness of breath and – in severe cases – neurological complications such as facial palsy, vision issues, and meningitis symptoms, including severe headaches and neck stiffness. Lyme disease impacts more than 300,000 people in the U.S. each year and over 30 million are at high or moderate risk for contracting the disease.

TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills ticks by blocking the parasite-specific GABA-CI channels. TP-05 is believed to be the only non-vaccine based therapeutic in development and is designed to rapidly provide systemic blood levels of lotilaner, and kill infected ticks attached to the human body before they can transmit the Borrelia bacteria that causes Lyme disease. In addition to the prevention of Lyme disease, Tarsus is also exploring TP-05 for the community prevention of malaria.

Tarsus is currently conducting a pivotal trial evaluating the efficacy and safety of TP-03, a topical ophthalmic formulation of lotilaner, for the treatment of Demodex blepharitis, a common ocular condition caused by an infestation of Demodex mites.

About TP-05
TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills parasites by inhibiting parasite-specific GABA-Cl channels. Tarsus is studying TP-05 for the prevention of Lyme disease. In July of 2021, Tarsus will initiate a Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) study to evaluate the safety, tolerability and pharmacokinetics (PK) of TP-05 in healthy volunteers. In addition to Lyme disease, Tarsus is also exploring TP-05 for the community prevention of malaria.

About Lyme Disease
Lyme disease is the most common vector-borne disease in the United States, transmitted to humans after the bite of a blacklegged tick infected by the bacterium Borrelia burgdorferi. Over 30 million Americans are at high or moderate risk of contracting Lyme disease and there are approximately 300,000 – 400,000 cases in the U.S. each year. People who spend extended amounts of time outdoors in wooded, grassy areas are at higher risk of getting the infection. Data from the Centers for Disease Control (CDC) shows that the risk of Lyme disease is spreading to new geographical areas, resulting in a significant need for prophylactic solutions. Currently, there are no FDA-approved pharmacological prophylactic options for Lyme disease.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in a pivotal Phase 2b/3 trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease.

Media Contact:
SuJin Oh
Shop PR
(917) 841-5213
sujin@shop-pr.com

Investor Contact:
Patti Bank
Westwicke Partners, an ICR company
(415) 513-1284
IR@tarsusrx.com

___________________

For more on Lotilaner:

  • https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-017-2471-3
  • https://vetmed.illinois.edu/pet_column/fda-alert-on-flea-medications/  Only medications in the isoxazoline class of flea and tick medications are under investigation at this time. This includes Bravecto, Nexgard, Credelio, and Simparica (brand names for fluralaner, afoxolaner, lotilaner, and sarolaner).
  • Credelio contains the ingredient, lotilaner, which is an antiparasitic drug that kills the fleas and ticks that live on your pet’s body surface. Lotilaner blocks the transfer of chloride ions from passing through cell membranes, which causes uncontrolled neuromuscular activity and results in the death of fleas and ticks. Credelio starts killing fleas within 4 hours of administration and kills over 99% of fleas within 8 hours of administration. Credelio starts killing ticks* in 4 hours and 98.7% killed within 8 hours. *(Ixodes ricinus)  Source
  • https://ivcjournal.com/isoxazoline-flea-and-tick/  On September 20, 2018, the U.S. Food and Drug Administration (FDA) warned animal caregivers and veterinarians about the risk of serious neurologic events, including seizures, muscle tremors and ataxia, in dogs and cats treated with certain flea and tick medications. The warning applies to medications in the isoxazoline class — specifically, NexGard (afoxalaner), Bravecto (fluralaner), Simparica (sarolaner) and Credelio (lotilaner). The FDA updated their release on April 22, 2019 to include another recently-approved product in the isoxazoline class — namely, Revolution Plus (selamectin and sarolaner topical solution). The isoxazoline class encompasses a group of azolyl phenyl chemical compounds originally developed as parasiticides about 20 years ago. They are now widely used around the world. Adverse reactions to these compounds appear to affect animals randomly, although those with certain chronic diseases, the young and elderly, and animals that are immune-compromised or have the genetic mutation of the MDR1 gene are at higher risk.

https://danielcameronmd.com/patient-facial-palsy-from-lyme-disease-fails-treatment/

PATIENT WITH FACIAL PALSY FROM LYME DISEASE FAILS TREATMENT

facial palsy from lyme disease in elderly man

Facial palsy, sometimes referred to as Bell’s palsy, is considered an early sign of Lyme disease. When the infection is diagnosed in the early stage it is typically easier to treat. However, this case report features an elderly patient with facial palsy from Lyme disease who remained ill following treatment.

In this case report, Hareem and colleagues describe a 71-year-old man with facial palsy from Lyme disease who failed treatment. The authors offer an inside look at what led up to the failed treatment.¹

Steroids associated with treatment failure?

The man was initially treated in August 2017 for an upper respiratory tract infection and prescribed the steroid dexamethasone. The previous year, he had a tick bite but no rash. One week later he was seen for a sore throat, right-sided ear pain, headache, dizziness, nausea, neck pain, and tinnitus. He had slight asymmetry of his smile.

Lyme disease Western blot test results were positive and the patient was prescribed doxycycline. However, several days later, the man returned with a complete facial palsy from Lyme disease. His condition had worsened.

“On his next visit, he complained of continuing right-sided headache and neck pain along with right-sided hearing loss, right-sided otalgia, dizziness, and nausea,” wrote the authors. His treatment was changed to cefuroxime.

Gait problems, hearing loss

Two weeks later his condition was even worse. “He continued to complain of gait instability and otalgia with hearing loss and neck pain,” wrote the authors. His treatment was changed to 30 days of doxycycline. He had an 80% hearing loss in the right ear and 25% in the left ear on audiology testing.

Authors’ conclusion

The man was diagnosed with “chronic Lyme disease from failed antibiotic therapy with simultaneous unilateral involvement of the seventh and eighth cranial nerves.”  He was prescribed an additional 4 weeks of doxycycline but remained ill. 

Wormer and colleagues previously discussed treatment failures in Lyme disease patients treated with steroids.2

Editor’s Note:  The 71-year-man never received a course of intravenous ceftriaxone. The authors did not discuss other diagnostic or treatment options.

References:
  1. Hareem A, Dabiri I, Zaheer N, Burakgazi AZ. Medically Refractory Neuroborreliosis Case Presented with Coexistance Involvements of Cranial 7 and 8 Nerves. Neurol Int. Mar 18 2021;13(1):125-129. doi:10.3390/neurolint13010012
  2. Wormser GP, Brady KC, Cho MS, Scavarda CA, McKenna D. Efficacy of a 14-day course of amoxicillin for patients with erythema migrans. Diagn Microbiol Infect Dis. Jun 2019;94(2):192-194. doi:10.1016/j.diagmicrobio.2019.01.003

____________________

For more:

https://childrenshealthdefense.org/defender/fda-warning-jj-vaccine-serious-rare-autoimmune-disorder/?

FDA to Add Warning to J&J Vaccine of ‘Serious But Rare’ Autoimmune Disorder

The U.S. Food and Drug Administration will announce a new warning on Johnson & Johnson’s COVID vaccine saying the shot is linked to Guillain–Barré syndrome. In April, the agency added a warning about blood clotting disorders to the J&J shot.

The U.S. Food and Drug Administration (FDA) will announce a new warning on Johnson & Johnson’s (J&J) COVID vaccine saying the shot has been linked to Guillain–Barré syndrome (GBS), a “serious but rare” autoimmune disorder. The Washington Post attributed the news to “four individuals familiar with the situation.”

According to The New York Times, the chances of developing GBS after receiving the J&J shot is three to five times higher than would be expected in the general population in the U.S.

About 100 preliminary reports in the U.S. of GBS have been detected after receiving J&J’s vaccine, the Centers for Disease Control and Prevention (CDC) said in a statement to CNN today. Most cases were reported about two weeks after vaccination, mostly in men 50 and older.

The CDC’s Advisory Committee on Immunization Practices (ACIP) is expected to discuss the GBS cases during an upcoming meeting, the CDC said.

GBS is a rare neurological disorder in which the body’s immune system mistakenly attacks part of its peripheral nervous system — the network of nerves located outside of the brain and spinal cord — and can range from a very mild case with brief weakness to paralysis, leaving the person unable to breathe independently.

While the cause of GBS is not fully known, it often follows infection with a virus and has been linked to other vaccines.

The FDA has concluded the benefits of the vaccine outweigh any danger, but will include the proviso in fact sheets about the drug for providers and patients.

“It’s not surprising to find these types of adverse events associated with vaccination,” said Dr. Luciana Borio, former acting chief scientist at the FDA. The data collected so far by the FDA, Borio said, suggest the vaccine’s benefits “continue to vastly outweigh the risks.”

Reports of GBS are rare, the CDC said, “but do likely indicate a small possible risk of this side effect following” the J&J vaccine.

Federal officials identified the 100 suspected cases of GBS among recipients of the J&J shot through the CDC’s Vaccine Adverse Events Reporting System (VAERS) — a federal monitoring system that relies on patients and health care providers to report adverse effects of vaccines.

According to the most recent data from VAERS, between Dec. 14, 2020 and July 2, there were 398 reports of GBS with 187 of cases attributed to Pfizer, 159 to Moderna and 76 cases to J&J.

No link has been found between GBS and mRNA COVID vaccines developed by Pfizer-BioNTech or Moderna despite reports in VAERS.

The VAERS database indicates onset of GBS symptoms after the J&J vaccine within about three weeks of vaccination, The New York Times reported. One recipient, a 57-year-old man from Delaware who had suffered both a heart attack and a stroke within the last four years, died in early April after he was vaccinated and developed GBS.

As The Defender reported July 8, a third grade teacher developed GBS three weeks after receiving J&J’s COVID vaccine. Stacie [last name unknown] went to the emergency room several times after getting the shot because she was experiencing numbness of the lower extremities, but was sent home when tests were inconclusive.

The numbness continued to progress and Stacie eventually lost her ability to stand and walk. She was then hospitalized and diagnosed with GBS.

Gary Spaulding was an active landscaper who experienced a severe headache after receiving J&J’s COVID vaccine, causing him to go to the emergency room. Doctors immediately diagnosed Spaulding with Lyme Disease. Treatment was started, but numbness and tingling in his extremities progressed. After doctors initiated tests to determine the cause of the escalating series of symptoms, Spaulding was diagnosed with GBS.

Doctors believe Spaulding’s immune system, which was fighting Lyme Disease, was overstimulated by the COVID vaccine causing it to attack the myelin — the protective insulation that surrounds nerves, including those in the brain and spinal cord.

Treatment was immediate and successful in arresting the progression of the disease, but not before Spaulding was almost completely paralyzed.

In April, The Defender reported on a Texas teenager diagnosed with GBS a few weeks after his first dose of the COVID-19 vaccine. The teen said he believed the vaccine was to blame, according to a local Houston news channel KPRC2 report.

“I wanted to get the vaccine,” said Wyatt McGlaun, a high school senior from The Woodlands. “I felt it was the right thing to do. I wanted to travel and enjoy my last summer before college.”

A few weeks after receiving the vaccine, McGlaun became weak and had difficulty walking. He was admitted to CHI St. Luke’s Health where he was diagnosed with GBS. News reports did not disclose which vaccine the teen received.

J&J linked to blood-clotting disorders

This is the second time J&J’s COVID vaccine has been linked to a severe adverse reaction. On April 13, federal officials temporarily paused the J&J shot after confirming health officials were investigating six cases of blood clots in the U.S.

During the April 23 meeting, the ACIP said it had found 15 women diagnosed with rare blood clots, including three who died. Only two of the women were older than 50, with the risk highest in women ages 30 to 39.

The CDC advisory safety committee said the link between blood clots and J&J’s COVID vaccine was “plausible,” but concluded the vaccine’s benefits still outweigh the risks and recommended the vaccine for persons 18 years of age and older in the U.S. under the FDA’s Emergency Use Authorization (EUA).

On April 26, the FDA amended it’s EUA for the J&J vaccine to reflect the risk of rare blood clots and said vaccinations could resume immediately.

© [7/12/21] Children’s Health Defense, Inc. This work is reproduced and distributed with the permission of Children’s Health Defense, Inc. Want to learn more from Children’s Health Defense? Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. Your donation will help to support us in our efforts.

____________________

**Comment**

Please note the case mentioned involving Lyme disease.  In cast you missed it:

Gary Spaulding was an active landscaper who experienced a severe headache after receiving J&J’s COVID vaccine, causing him to go to the emergency room. Doctors immediately diagnosed Spaulding with Lyme Disease. Treatment was started, but numbness and tingling in his extremities progressed. After doctors initiated tests to determine the cause of the escalating series of symptoms, Spaulding was diagnosed with GBS.

Doctors believe Spaulding’s immune system, which was fighting Lyme Disease, was overstimulated by the COVID vaccine causing it to attack the myelin — the protective insulation that surrounds nerves, including those in the brain and spinal cord.

Treatment was immediate and successful in arresting the progression of the disease, but not before Spaulding was almost completely paralyzed.

Please notice the important issue of the immune system – OVERSTIMULATED BY THE COVID “VACCINE”. This has been my premise from get-go, yet even some LLMD’s are recommending the COVID “vaccine” to severely ill Lyme//MSIDS patients.

You are duly warned.

Please see the mounting injuries and deaths here.

Lastly, labeling something as “rare” is the CDC/FDA’s MO. They’ve been doing this for decades. It’s rare until you are the sorry-sucker affected. How many cases are unreported?

For a little history lesson, please see that the Swine Flu vaccine was dumped after just a few (3) deaths!: https://www.nytimes.com/1976/10/13/archives/swine-flu-prograrm-is-halted-in-9-states-as-3-die-after-shots.html

The reason for this is simple: it was before vaccine manufacturers got a free pass.

According to 42 U.S. Code § 300aa–22, “No vaccine manufacturer shall be liable in a civil action for damages arising from a vaccine-related injury or death associated with the administration of a vaccine after October 1, 1988, if the injury or death resulted from side effects that were unavoidable even though the vaccine was properly prepared and was accompanied by proper directions and warnings.”

In other words, companies that manufacture vaccines are not liable if someone has an allergic reaction or injury after being vaccinated.  Source

https://www.betterhealthguy.com/nathancrista2021

I had the opportunity to attend “A Comprehensive & Practical Review of Mold Toxicity and its Complications” held online on April 24-25, 2021.  This event was a wonderful collaboration between Neil Nathan, MD and Jill Crista, ND.

Disclaimer: Nothing in this text is intended to serve as medical advice. All medical decisions should be made only with the guidance of your own personal licensed medical authority.

Disclaimer: This information was taken as notes during the training course and may not represent the exact statements of the speakers. Errors and/or omissions may be present.

Note: As this information may be updated as any errors are found, I kindly request that you link to this single source of information rather than copying the content below. If any updates or corrections are made, this will help to ensure that anyone reading this is getting the most current and accurate information available.

Go to top link for article and notes

____________________

For more:

Mold toxicity is a big deal and needs to be addressed before some Lyme/MSIDS patients experience improvement.  Again, Lyme literate doctors are educated in these issues.